Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-04-01
2010-06-22
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S049000, C514S243000
Reexamination Certificate
active
07741334
ABSTRACT:
A method of treating viral infections, particularly Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV), by administering a low dose of Elvucitabine to a patient suffering viral infection is provided herein. The Elvucitabine dosages provided herein for effective anti-viral therapy are approximately 10-fold less than the effective dosages of currently marketed reverse transcriptase inhibitors. The Elvucitabine dosage may be given BID, daily, once every 48 hours, or once weekly. Also provided herein are packaged pharmaceutical formulations comprising Elvucitabine and instructions for treating a viral infection by administering a low BID, daily, once/48 hour, or weekly dosage of Elvucitabine. The low dose Elvucitabine formulations provided herein have the additional benefit of improving patient compliance with anti-viral therapy.
REFERENCES:
patent: 5703058 (1997-12-01), Schinazi et al.
patent: 6908924 (2005-06-01), Watanabe et al.
patent: WO 98/57648 (1998-12-01), None
patent: 2000403014 (2000-07-01), None
patent: 2005055955 (2005-06-01), None
patent: 2005097618 (2005-10-01), None
Shi, J., McAtee, J., Wirtz, S.S., Tharnish, P., Juodawlkis, A., Liotta, D.C., and R.F. Schinazi, 1999. Synthesis and biological evaluation of 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (D4FC) analogue: Discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase. J. Med. Chem. 42:859-867.
Chen, Shu-Hui. “Comparative Evaluation of L-Fd4c and Related Nucleotide Analogs as Promising Antiviral Agents,” Current Medicinal Chemistry (2002) 9: 899-912.
Dutschman, Ginger E. et al. “Metabolism of 2′,3′-Dideoxy-2′,3′-Didehydro-Beta-L(−)-5-Flourocytidine and Its Activity in Combination with Clinically Approved Anti-Human Immodeficiency Virus Beta-D(+) Nucleoside Analogs in Vitro,” Antimicrobial Agents and Chemotherapy (1998) 42(7): 1799-1804.
Mickle, Travis and Vasu Nair. “Anti-Human Immumodeficiency Virus Activities of Nucleosides and Nucleotides: Correlation with Molecular Electrostatic Potential Data,” Antimicrobial Agents and Chemotherapy (2000) 44(11): 2939-2947.
International Search Report for PCT/US05/11538.
Written Opinion of the International Searching Authority for PCT/US05/11539.
International Search Report for PCT/US05/037597, 2005.
Written Opinion for US05/037597, 2005.
Gish, et al., “Dose range study of pharmacokinetic, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection,” Antimicrob. Agens Chemother., (2002), 46(6): 1734-1740 (abstract only) .
Johnson, et al., “Clinical Pharmacokinetics of Lannuvudine,” Clinical Pharmacokinetic, (1999), 36(1): 41-66 (abstract only).
Patel, J. et al., “ACH-126443 Achillion/Yale University,” Current Opinion in Investigation Drugs, (2002), 3(11): 1580-1584.
Sorberra, L.A., et al., “ACH-126443 Anti-HBV, Anti-HIV,” Drugs of the Future, (2002), 27(12):1131-1140.
Zoulim, F., et al.,“Animal model for the study of HBV infection and the evaluationof new anti-HBV strategies,” Journal of Gastroenterology and Hepatology, (2002), 17: S460-S463.
Achillion Pharmaceuticals, Inc.
Cantor & Colburn LLP
Jean-Louis Samira
Padmanabhan Sreeni
LandOfFree
Low dose therapy for treating viral infections does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Low dose therapy for treating viral infections, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Low dose therapy for treating viral infections will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4245262